Physician profile
David Fielder
NPI 1821084377
$2,006.27
in general payments reported to CMS, 2019-2025
28 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $247 · 2021: $475 · 2022: $261 · 2023: $115 · 2024: $184 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $542.86 | 2019-2024 | Evenity, Prolia |
| Pfizer INC. | $215.43 | 2019-2024 | |
| Abbott Laboratories | $192.01 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $175.99 | 2019-2024 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.49 | 2019-2024 | Xifaxan |
| Novo Nordisk INC | $116.73 | 2019-2021 | |
| Medtronic, INC. | $80.59 | 2022 | |
| Janssen Pharmaceuticals, INC | $68.61 | 2019 | |
| Astellas Pharma US INC | $45.30 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.87 | 2021 | |
| Novartis Pharmaceuticals Corporation | $37.65 | 2022-2025 | |
| Genentech USA, INC. | $34.77 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.40 | 2023-2024 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $30.12 | 2020 | |
| Abbvie INC. | $27.01 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $26.80 | 2019 | |
| Glaxosmithkline, LLC. | $24.83 | 2020-2023 | Trelegy Ellipta |
| Amarin Pharma, INC. | $24.55 | 2022 | |
| Boston Scientific Corporation | $22.70 | 2024 | Watchman Access System |
| Viatris Specialty LLC | $22.50 | 2025 | Yupelri |
| Daiichi Sankyo INC. | $19.13 | 2024 | Injectafer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.77 | 2025 | Caplyta |
| Mylan Specialty L.P. | $17.49 | 2022 | |
| Sumitomo Pharma America, INC. | $16.20 | 2025 | Gemtesa |
| Antares Pharma, INC. | $15.57 | 2025 | Xyosted |
| Eisai INC. | $14.66 | 2020 | |
| Sunovion Pharmaceuticals INC. | $13.85 | 2021 | |
| Phathom Pharmaceuticals, INC. | $12.39 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Fielder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.